SELLAS Life Sciences Group, Inc. (SLS)

2.04 +0.01 (+0.49%) USD  |  NASDAQ  |  Dec 15, 13:33
More

SELLAS Life Sciences Group Research and Development Expense (Quarterly): 4.216M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for SLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Geron Corp. 21.07M
GT Biopharma, Inc. 0.634M
ADMA Biologics, Inc. 1.528M
NovaBay Pharmaceuticals, Inc. --
Palatin Technologies, Inc. 2.526M